Cancer

Giredestrant and everolimus extended progression-free survival after CDK4/6 treatment

In the evERA trial, median progression-free survival was 10.0 months with giredestrant and everolimus for patients with ESR1-mutated tumors.

Reported by 2 outlets Thursday, October 1, 2026

Cancer cells under a fluorescence microscope
Photo: CC0

In the phase III evERA trial, giredestrant plus everolimus extended progression-free survival for people with advanced ER-positive/HER2-negative breast cancer whose disease had progressed after CDK4/6 inhibitor treatment, MedPage Today reported. Among patients with ESR1-mutated tumors, median progression-free survival was 10.0 months with the combination and 5.5 months with investigator-selected endocrine therapy plus everolimus.

The trial included 373 patients from 13 countries, and ESR1-mutated tumors accounted for 55% of participants. In the overall population, median progression-free survival with the combination was 8.8 months. Any-grade adverse events occurred in 97-99% of patients, and fatal adverse events occurred in 2.7% of each group.

The estimated 18-month overall survival among patients with ESR1-mutated tumors was 71.5% with giredestrant and everolimus and 50.9% in the control group.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.